CA2593232A1 - Prevention of respiratory infections in fowl - Google Patents
Prevention of respiratory infections in fowl Download PDFInfo
- Publication number
- CA2593232A1 CA2593232A1 CA002593232A CA2593232A CA2593232A1 CA 2593232 A1 CA2593232 A1 CA 2593232A1 CA 002593232 A CA002593232 A CA 002593232A CA 2593232 A CA2593232 A CA 2593232A CA 2593232 A1 CA2593232 A1 CA 2593232A1
- Authority
- CA
- Canada
- Prior art keywords
- substance
- met
- sar9
- administered
- domestic fowl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
Substance P or its analogs are useful for treating and protecting against respiratory syndromes in avian populations. The active agents can be administered via aerosol, in dressed feed, or by other methods. Disease rates are reduced by substance P treatment.
Description
PREVENTION OF RESPIRATORY INFECTIONS IN FOWL
BACKGROUND OF THE INVENTION
Domestic and captured birds as well as wild birds are susceptible to influenza type A virus infections. These viruses are highly pathogenic and can cause mortality up to 100 % in domestic flocks. Avian paramyxoviruses cause diseases such as Newcastle disease (ND) which can have severe negative effects on domestic flocks.
Other respiratory viruses affecting fowl include infectious bronchitis virus and avian pneumovirus. While these effects are felt economically by producers and consumers, they also present public healtli issues. Birds are thought to provide a reservoir for viruses that infect human populations.
There is a continuing need in the art for means of controlling respiratory viral infections in bird populations.
SUMMARY OF THE INVENTION
According to one embodiment of the invention a method is provided for preventing respiratory viral infections in domestic fowl. An effective amount of an agent in admixture with feed is administered to domestic fowl. The agent is selected from the group consisting of substance P, [Met-OH11]-substance P, [Met-OMejl]-substance P, [Nle"] -substance P, [Pro9] -substance P, [Sarl-substance P, [Tyr8] -substance P, Sar9, Met (02) 11-Substance P, and [p-Cl-Phe7 8]-substance P.
The infection rate is decreased by ineans of the administration..
According to another aspect of the invention another method is provided for preventing respiratory viral infections in domestic fowl. An effective amount of an agent in an aerosol is administered to domestic fowl. The agent is selected from the group consisting of: substance P, [Met-OHII]-substance P, [Met-OMell]-substance P, [Nlell]-substance P, [Pro9] -substance P, [Sar9]-substance P, [Tyr8] -substance P, Sar9, Met (02) 11-Substance P, and [p-Cl-Phe7'8]-substance P. The rate of infection is decreased by the administration..
According to another aspect of the invention another method is provided for preventing respiratory viral infections in domestic fowl. An effective amount of an agent is administered to domestic fowl. The agent is selected from the group consisting of: substance P, [Met-OHIi]-substance P, [Met-OMeIl]-substance P, [Nlell]-substance P, [Pro9]-substance P, [Sar9] -substance P, [Tyr$]-substance P, Sar9, Met (02) Substance P, and [p-Cl-Phe7'$]-substance P. The mode of administration is selected from the group consisting of intramuscular, intravenous, intrabronchial, sublingual, intratracheal, and subcutaneous. The rate of infection is decreased by the administration.
DETAILED DESCRIPTION OF THE INVENTION
It is a discovery of the present inventor that Substance P and its bioactive analogs, such as Sar9, Met (02) 11-Substance P, are beneficial preventatives against respiratory virus infections in domestic fowl. Substance P and its analogs potentiate the lung's immune response against respiratory viruses. Substance P and its analogs can be used to prophylactically treat poultry to minimize infection and to minimize spread of infection between birds and to other species, including humans.
BACKGROUND OF THE INVENTION
Domestic and captured birds as well as wild birds are susceptible to influenza type A virus infections. These viruses are highly pathogenic and can cause mortality up to 100 % in domestic flocks. Avian paramyxoviruses cause diseases such as Newcastle disease (ND) which can have severe negative effects on domestic flocks.
Other respiratory viruses affecting fowl include infectious bronchitis virus and avian pneumovirus. While these effects are felt economically by producers and consumers, they also present public healtli issues. Birds are thought to provide a reservoir for viruses that infect human populations.
There is a continuing need in the art for means of controlling respiratory viral infections in bird populations.
SUMMARY OF THE INVENTION
According to one embodiment of the invention a method is provided for preventing respiratory viral infections in domestic fowl. An effective amount of an agent in admixture with feed is administered to domestic fowl. The agent is selected from the group consisting of substance P, [Met-OH11]-substance P, [Met-OMejl]-substance P, [Nle"] -substance P, [Pro9] -substance P, [Sarl-substance P, [Tyr8] -substance P, Sar9, Met (02) 11-Substance P, and [p-Cl-Phe7 8]-substance P.
The infection rate is decreased by ineans of the administration..
According to another aspect of the invention another method is provided for preventing respiratory viral infections in domestic fowl. An effective amount of an agent in an aerosol is administered to domestic fowl. The agent is selected from the group consisting of: substance P, [Met-OHII]-substance P, [Met-OMell]-substance P, [Nlell]-substance P, [Pro9] -substance P, [Sar9]-substance P, [Tyr8] -substance P, Sar9, Met (02) 11-Substance P, and [p-Cl-Phe7'8]-substance P. The rate of infection is decreased by the administration..
According to another aspect of the invention another method is provided for preventing respiratory viral infections in domestic fowl. An effective amount of an agent is administered to domestic fowl. The agent is selected from the group consisting of: substance P, [Met-OHIi]-substance P, [Met-OMeIl]-substance P, [Nlell]-substance P, [Pro9]-substance P, [Sar9] -substance P, [Tyr$]-substance P, Sar9, Met (02) Substance P, and [p-Cl-Phe7'$]-substance P. The mode of administration is selected from the group consisting of intramuscular, intravenous, intrabronchial, sublingual, intratracheal, and subcutaneous. The rate of infection is decreased by the administration.
DETAILED DESCRIPTION OF THE INVENTION
It is a discovery of the present inventor that Substance P and its bioactive analogs, such as Sar9, Met (02) 11-Substance P, are beneficial preventatives against respiratory virus infections in domestic fowl. Substance P and its analogs potentiate the lung's immune response against respiratory viruses. Substance P and its analogs can be used to prophylactically treat poultry to minimize infection and to minimize spread of infection between birds and to other species, including humans.
Substance P(RPKPQQFFGLM-Nff2; SEQ ID NO: 1) or a bioactive analog thereof such as Sar9, Met (02) 11-Substance P can be adniinistered to prevent or treat respiratory virus infections. The bioactive analog can be selected from the group consisting of [Met-OHII]-substance P, [Met-OMeli]-substance P, [N1e11]-substance P, [Pro9] -substance P, [Sar9] -substance P, [Tyr$]-substance P, Sar9, Met (02) Substance P, and [p-Cl-Phe7~8]-substance P. Other compounds which function in the same way can be identified by their ability to compete with substance P for binding to its receptor (NK-1) or for their ability to agonize the NK-1 receptor. Routine assays for such activities are known in the art and can be used.
The substance P or analog can be administered by any method known in the art, including via aerosol iiihalation and via admixture with feed.
Intravenous, intratracheal, intrabronchial, intramuscular, sublingual, and oral administrations can also be used. Preferred dosages include 0.05 to 5 nanomolar substance P or analog for intravenous administration, preferably 0.1 to 2 nanomolar, and more preferably 0.5 to 1.5 nanomolar. For aerosol administration dosages include 0.05 to 75 micromolar substance P or analog, preferably 0.1 to 2 micromolar, and more preferably 0.5 to 1.5 microinolar. Typical concentration ranges of substance P or its bioactive analog in the aerosol adininistered is between 0.001 and 10 M. It can be advantageously administered as a liquid at a concentration between about 0.1 and 10 M.
Bioactive analogs, according to the invention are those which act as competitive inliibitors of SP by binding to the SP receptor (NK-1 receptor).
The analogs 'may be agonists of the NK-1 receptor. Other derivatives as are laiown in the art and commercially available (e.g., from Sigma) can be used. In addition, substance P
fraginents and derivatized substance P fragments may also be used.
Substitution, deletion, or insertion of one to eight amino acid residues, and preferably from one to three amino acid residues, will lead to analogs which can be routinely tested for biological activity. In addition, functional groups may be modified on SP
while retaining the same amino acid backbone. Again, routine testing will determine which of such modifications do not adversely affect biological activity.
Suitable devices for adininistering the aerosol of the present invention include nebulizers as well as hand-held aerosol "puffer" devices. Suitable treatment regimens for treatment according to the present invention include one-time, monthly, weekly, daily or multiple daily treatment by aerosol. Frequency may depend on the immediate risk of infection in a geographical area at a particular time. Other modes of treatment include continual transdermal infusion; intravenous, intramuscular, sublingual, and subcutaneous injections; and oral administration. Suitable formulations of substance P
for administration are any which are veterinarially acceptable and in which the substance P or bioactive analog retains its biological activity. Generally, such formulations are substance P dissolved in normal saline, which is optionally sterile.
Other formulations for changing absoiption and half-life characteristics can be used, including liposomal formulations and slow-release formulations.
Disease features of respiratory viral infections include Clara cell necrosis, increased pulmonary alveolar macrophage nuniber, neutrophil nuniber, alveolar-capillary barrier membrane damage, surfactant depletion, and increased 6-keto-PGFIn, and PGE2 concentrations. These disease features are reduced in a population by the prophylactic administrations of the present invention. Decreases in the disease features or rates of infection in a population of at least 10 %, 15 %, 20 %, 25%, 30 %, 35 %, 40 %, or 50 % are desirable. Even greater decreases are preferred.
The substance P or analog can be administered by any method known in the art, including via aerosol iiihalation and via admixture with feed.
Intravenous, intratracheal, intrabronchial, intramuscular, sublingual, and oral administrations can also be used. Preferred dosages include 0.05 to 5 nanomolar substance P or analog for intravenous administration, preferably 0.1 to 2 nanomolar, and more preferably 0.5 to 1.5 nanomolar. For aerosol administration dosages include 0.05 to 75 micromolar substance P or analog, preferably 0.1 to 2 micromolar, and more preferably 0.5 to 1.5 microinolar. Typical concentration ranges of substance P or its bioactive analog in the aerosol adininistered is between 0.001 and 10 M. It can be advantageously administered as a liquid at a concentration between about 0.1 and 10 M.
Bioactive analogs, according to the invention are those which act as competitive inliibitors of SP by binding to the SP receptor (NK-1 receptor).
The analogs 'may be agonists of the NK-1 receptor. Other derivatives as are laiown in the art and commercially available (e.g., from Sigma) can be used. In addition, substance P
fraginents and derivatized substance P fragments may also be used.
Substitution, deletion, or insertion of one to eight amino acid residues, and preferably from one to three amino acid residues, will lead to analogs which can be routinely tested for biological activity. In addition, functional groups may be modified on SP
while retaining the same amino acid backbone. Again, routine testing will determine which of such modifications do not adversely affect biological activity.
Suitable devices for adininistering the aerosol of the present invention include nebulizers as well as hand-held aerosol "puffer" devices. Suitable treatment regimens for treatment according to the present invention include one-time, monthly, weekly, daily or multiple daily treatment by aerosol. Frequency may depend on the immediate risk of infection in a geographical area at a particular time. Other modes of treatment include continual transdermal infusion; intravenous, intramuscular, sublingual, and subcutaneous injections; and oral administration. Suitable formulations of substance P
for administration are any which are veterinarially acceptable and in which the substance P or bioactive analog retains its biological activity. Generally, such formulations are substance P dissolved in normal saline, which is optionally sterile.
Other formulations for changing absoiption and half-life characteristics can be used, including liposomal formulations and slow-release formulations.
Disease features of respiratory viral infections include Clara cell necrosis, increased pulmonary alveolar macrophage nuniber, neutrophil nuniber, alveolar-capillary barrier membrane damage, surfactant depletion, and increased 6-keto-PGFIn, and PGE2 concentrations. These disease features are reduced in a population by the prophylactic administrations of the present invention. Decreases in the disease features or rates of infection in a population of at least 10 %, 15 %, 20 %, 25%, 30 %, 35 %, 40 %, or 50 % are desirable. Even greater decreases are preferred.
954277_1 SEQUENCE LISTING
<110> Witten, Mark <120> PREVENTION OF RESPIRATORY INFECTIONS IN
FOWL
<130> 003413.00041 <150> 60/641,153 <151> 2005-01-05 <160> 1 <170> FastSEQ for windows version 4.0 <210> 1 <211> 11 <212> PRT
<213> Homo sapiens <400> 1 Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met
<110> Witten, Mark <120> PREVENTION OF RESPIRATORY INFECTIONS IN
FOWL
<130> 003413.00041 <150> 60/641,153 <151> 2005-01-05 <160> 1 <170> FastSEQ for windows version 4.0 <210> 1 <211> 11 <212> PRT
<213> Homo sapiens <400> 1 Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met
Claims (16)
1. A method of preventing respiratory viral infections in domestic fowl, comprising:
administering to domestic fowl an effective amount of an agent in admixture with feed, said agent selected from the group consisting of: substance P, [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9] -substance P, [Sar9] -substance P, [Tyr8]-substance P, Sar9, Met (0 2) Substance P, and [p-Cl-Phe7,8]-substance P, whereby infection rate is decreased.
administering to domestic fowl an effective amount of an agent in admixture with feed, said agent selected from the group consisting of: substance P, [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9] -substance P, [Sar9] -substance P, [Tyr8]-substance P, Sar9, Met (0 2) Substance P, and [p-Cl-Phe7,8]-substance P, whereby infection rate is decreased.
2. A method of preventing respiratory viral infections in domestic fowl, comprising:
administering to domestic fowl an effective amount of an agent in an aerosol, said agent selected from the group consisting of substance P, [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9]-substance P, [Sar9]-substance P, [Tyr8]-substance P, Sar9, Met (0 2) 11-Substance P, and [p-Cl-Phe7,8]-substance P, whereby infection rate is decreased.
administering to domestic fowl an effective amount of an agent in an aerosol, said agent selected from the group consisting of substance P, [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9]-substance P, [Sar9]-substance P, [Tyr8]-substance P, Sar9, Met (0 2) 11-Substance P, and [p-Cl-Phe7,8]-substance P, whereby infection rate is decreased.
3. A method of preventing respiratory viral infections in domestic fowl, comprising:
administering to domestic fowl an effective amount of an agent selected from the group consisting of: substance P, [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9]-substance P, [Sar9]-substance P, [Tyr8]-substance P, Sar9, Met (0 2) 11-Substance P, and [p-Cl-Phe7,8]-substance P, wherein said administering is accomplished by a mode selected from the group consisting of intramuscular, intravenous, intrabronchial, sublingual, intratracheal, and subcutaneous, whereby infection rate is decreased.
administering to domestic fowl an effective amount of an agent selected from the group consisting of: substance P, [Met-OH11]-substance P, [Met-OMe11]-substance P, [Nle11]-substance P, [Pro9]-substance P, [Sar9]-substance P, [Tyr8]-substance P, Sar9, Met (0 2) 11-Substance P, and [p-Cl-Phe7,8]-substance P, wherein said administering is accomplished by a mode selected from the group consisting of intramuscular, intravenous, intrabronchial, sublingual, intratracheal, and subcutaneous, whereby infection rate is decreased.
4. The method of claim 1, 2, or 3 wherein the domestic fowl is a chicken.
5. The method of claim 1, 2, or 3 wherein the domestic fowl is a turkey.
6. The method of claim 1, 2, or 3 wherein the domestic fowl is a duck.
7. The method of claim 1, 2, or 3 wherein the domestic fowl is a goose.
8. The method of claim 1, 2, or 3 wherein Sar9, Met (0 2) 11-Substance P is administered.
9. The method of claim 1, 2, or 3 wherein Substance P is administered.
10. The method of claim 1, 2, or 3 wherein [Met-OH11]-substance P is administered.
11. The method of claim 1, 2, or 3 wherein [Met-OMe11]-substance P is administered.
12. The method of claim 1, 2, or 3 wherein [Nle11]-substance P is administered.
13. The method of claim 1, 2, or 3 wherein [Pro9]-substance P is administered.
14. The method of claim 1, 2, or 3 wherein [Sar9]-substance P is administered.
15. The method of claim 1, 2, or 3 wherein [Tyr8]-substance P is administered.
16. The method of claim 1, 2, or 3 wherein [p-Cl-Phe7,8]-substance P is administered.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64115305P | 2005-01-05 | 2005-01-05 | |
| US60/641,153 | 2005-01-05 | ||
| PCT/US2005/042601 WO2006073603A1 (en) | 2005-01-05 | 2005-11-23 | Prevention of respiratory infections in fowl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2593232A1 true CA2593232A1 (en) | 2006-07-13 |
Family
ID=36647801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002593232A Abandoned CA2593232A1 (en) | 2005-01-05 | 2005-11-23 | Prevention of respiratory infections in fowl |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1838216A4 (en) |
| JP (1) | JP2008526741A (en) |
| AU (1) | AU2005323304A1 (en) |
| CA (1) | CA2593232A1 (en) |
| SG (1) | SG123646A1 (en) |
| WO (1) | WO2006073603A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979513B (en) * | 2010-09-10 | 2012-06-06 | 福建省农业科学院畜牧兽医研究所 | Duck-origin paramyxovirus attenuated lapinized Chineses (LC) strain and application thereof to the preparation of vaccines |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945508A (en) * | 1996-07-23 | 1999-08-31 | Witten; Mark L. | Substance P treatment for immunostimulation |
| US20070155667A1 (en) * | 2003-04-14 | 2007-07-05 | Immuneregen Biosciences, Inc. | Acute respiratory syndromes |
-
2005
- 2005-01-27 SG SG200500467A patent/SG123646A1/en unknown
- 2005-11-23 WO PCT/US2005/042601 patent/WO2006073603A1/en active Application Filing
- 2005-11-23 EP EP05849894A patent/EP1838216A4/en not_active Withdrawn
- 2005-11-23 AU AU2005323304A patent/AU2005323304A1/en not_active Abandoned
- 2005-11-23 CA CA002593232A patent/CA2593232A1/en not_active Abandoned
- 2005-11-23 JP JP2007549376A patent/JP2008526741A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG123646A1 (en) | 2006-07-26 |
| EP1838216A4 (en) | 2010-02-10 |
| WO2006073603A1 (en) | 2006-07-13 |
| JP2008526741A (en) | 2008-07-24 |
| EP1838216A1 (en) | 2007-10-03 |
| AU2005323304A1 (en) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2817787C (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
| US20140154288A1 (en) | Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response | |
| WO2005060352A2 (en) | Antiviral preparations obtained from a natural cinnamon extract | |
| CA2593232A1 (en) | Prevention of respiratory infections in fowl | |
| MXPA06013050A (en) | Treatment or prevention of respiratory viral infections with immunomodulator compounds. | |
| US20100267616A1 (en) | Acute respiratory syndromes | |
| WO2022131922A1 (en) | Cath2 derivatives for stimulating innate immune memory | |
| Yu et al. | Ghrelin attenuates infectious bursal disease virus–induced early inflammatory response and bursal injury in chicken | |
| MXPA05011304A (en) | Treatment or prevention of respiratory viral infections with alpha thymosin peptides. | |
| US20070238661A1 (en) | Substance P treatment for hepatitis C | |
| CA2660856A1 (en) | Prophylactic and therapeutic treatment of avian influenza infections in animals | |
| US20180250602A1 (en) | Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response | |
| CN117279934A (en) | CATH2 and derivatives thereof for inhibiting streptococcus suis | |
| WO2022170396A1 (en) | Agents and methods for therapy and prophylaxis | |
| AR031405A1 (en) | METHODS AND VACCINES TO CONFERENCE PROTECTION IN OVO AGAINST TURKEY'S RHINOTRACHISIS | |
| AU2012255594A1 (en) | Papaya Mosaic Virus compositions and uses thereof for stimulation of the innate immune response | |
| WO2013028658A1 (en) | Method for preventing or treating a bacterial infection | |
| TH75093B (en) | Prevention of respiratory infection in poultry | |
| TH75093A (en) | Prevention of respiratory infection in poultry | |
| WO2016169571A1 (en) | Pharmaceutical product for treatment & prophylaxis of viral/ microbial infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |